Informed Prostate Cancer Patient Support

IPCSG Newsletter · Research on the Horizon The JANX014 Trial A "double-masked" T-cell engager for advanced prostate cancer has entered its first human study — developed by a San Diego company and being tested close to home. Prepared for the Informed Prostate Cancer Support Group · September 2026 Bottom Line Up Front JANX014 is an experimental prostate-cancer immunotherapy now in its earliest stage of human testing (Phase 1) for men with metastatic castration-resistant prostate cancer (mCRPC) . It is a "double-masked" T-cell engager — a drug engineered to stay switched off in the bloodstream and turn on only after it reaches the tumor, an approach meant to widen the safety margin and reduce the immune-overactivation reaction (cytokine release syndrome) that has limited earlier drugs of this type. It is made by San Diego–based Janux Therapeutics , and the study is recruiting at six U.S. centers — the first of which is UC San Diego's Moore...

Scientists find a new weakness in treatment-resistant prostate cancer | ScienceDaily IPCSG  Informed Prostate Cancer Support Group Research Update - Treatment Resistance · Precision Medicine A New Drug-Pairing Strategy for Treatment-Resistant Prostate Cancer When prostate cancer changes its identity to dodge hormone therapy, one drug may not be enough. A University of Michigan team makes the case for hitting the disguise from both directions at once. Prepared for the IPCSG Newsletter  •  September 2026 Bottom Line Up Front Some advanced prostate cancers escape hormone-blocking drugs by physically changing what kind of cell they are — a process called transdifferentiation or lineage plasticity . Researchers at the University of Michigan Rogel Cancer Center report that this escape has two moving parts, and that pairing two classes of “epigenetic” drugs — a BET bromodomain inhibitor and a DNMT inhibitor — blocked both parts and slowed tumo...